U.S. Homeland Security Ends TSA Union Contract, Prompting Legal Challenge 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Brazil Arrests Former Peruvian Foreign Minister Augusto Blacker Miller in International Fraud Case 
International Outcry Grows Over Re-Arrest of Nobel Laureate Narges Mohammadi in Iran 
Federal Judge Orders Restoration of SEVIS Status for Tufts PhD Student Rumeysa Ozturk 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Preservation Group Sues Trump Administration to Halt $300 Million White House Ballroom Project 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Bolivia’s Ex-President Luis Arce Detained in Embezzlement Probe 
Environmental Group Sues to Block Trump Image on U.S. National Park Passes 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Jimmy Lai Convicted Under Hong Kong National Security Law in Landmark Case 
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee 
Bolsonaro’s Defense Requests Hospital Transfer and Humanitarian House Arrest 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Judge Orders Return of Seized Evidence in Comey-Related Case, DOJ May Seek New Warrant 
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizer’s RSV vaccine, Abrysvo, which GSK claimed infringed on its own RSV shot, Arexvy. The two pharmaceutical giants filed to drop the case with prejudice in Delaware federal court, preventing it from being refiled. Neither company has commented publicly or disclosed if a settlement was reached.
GSK originally sued Pfizer in 2023, alleging that Abrysvo violated patents related to antigen technology used in Arexvy. According to GSK, Pfizer’s RSV vaccine development began in 2013, several years after GSK had started work on its version. Pfizer denied the allegations, arguing that GSK’s patents were invalid. In a related case, a UK court sided with Pfizer and invalidated similar GSK patents in 2023.
The U.S. Food and Drug Administration has approved RSV vaccines from GSK, Pfizer, and Moderna (NASDAQ:MRNA). Arexvy, GSK’s RSV shot, currently leads U.S. sales in this growing vaccine market. RSV, or respiratory syncytial virus, causes mild cold-like symptoms but can lead to serious respiratory illness, especially in infants and older adults.
The patent battle over RSV vaccines highlights intensifying competition in the global vaccine market. Despite dropping this particular case, legal tensions remain between GSK and Pfizer. GSK has another ongoing U.S. lawsuit claiming Pfizer’s COVID-19 vaccine, Comirnaty, infringes on its patented technology.
As leading pharmaceutical firms compete for dominance in respiratory vaccines, patent disputes are likely to continue. RSV vaccine sales are expected to grow as global demand rises, making this a critical area for innovation and legal scrutiny.
